Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis
J Hemelaar, R Elangovan, J Yun… - The Lancet infectious …, 2019 - thelancet.com
Background Global genetic diversity of HIV-1 is a major challenge to the development of HIV
vaccines. We aimed to estimate the regional and global distribution of HIV-1 subtypes and …
vaccines. We aimed to estimate the regional and global distribution of HIV-1 subtypes and …
The origin and diversity of the HIV-1 pandemic
J Hemelaar - Trends in molecular medicine, 2012 - cell.com
This review examines the enormous progress that has been made in the past decade in
understanding the origin of HIV, HIV genetic variability, and the impact of global HIV diversity …
understanding the origin of HIV, HIV genetic variability, and the impact of global HIV diversity …
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries
and regions of the world, and is undoubtedly the defining public-health crisis of our time …
and regions of the world, and is undoubtedly the defining public-health crisis of our time …
The challenge of HIV-1 subtype diversity
HIV-1 has evolved multiple mechanisms to elude immune control. The view of virus as
classifiable into distinct subtypes needs to reflect the reality of the constant emergence of …
classifiable into distinct subtypes needs to reflect the reality of the constant emergence of …
Rationale and uses of a public HIV drug‐resistance database
RW Shafer - The Journal of infectious diseases, 2006 - academic.oup.com
Abstract Knowledge regarding the drug resistance of human immunodeficiency virus (HIV) is
critical for surveillance of drug resistance, development of antiretroviral drugs, and …
critical for surveillance of drug resistance, development of antiretroviral drugs, and …
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
MS Hirsch, HF Günthard, JM Schapiro… - Clinical Infectious …, 2008 - academic.oup.com
Resistance to antiretroviral drugs remains an important limitation to successful human
immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment …
immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment …
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications
Human immunodeficiency virus type 1 (HIV-1) is the causative agent of AIDS (10, 38, 105,
114). It is characterized by extensive and dynamic genetic diversity, generating variants …
114). It is characterized by extensive and dynamic genetic diversity, generating variants …
HIV‐1 genetic variability and clinical implications
Despite advances in antiretroviral therapy that have revolutionized HIV disease
management, effective control of the HIV infection pandemic remains elusive. Beyond the …
management, effective control of the HIV infection pandemic remains elusive. Beyond the …
[HTML][HTML] HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
RW Shafer, JM Schapiro - AIDS reviews, 2008 - ncbi.nlm.nih.gov
More than 200 mutations are associated with antiretroviral resistance to drugs belonging to
six licensed antiretroviral classes. More than 50 reverse transcriptase mutations are …
six licensed antiretroviral classes. More than 50 reverse transcriptase mutations are …
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
Objectives: Monitoring regional levels of transmitted HIV-1 resistance informs treatment
guidelines and provides feedback on the success of HIV-1 prevention efforts. Surveillance …
guidelines and provides feedback on the success of HIV-1 prevention efforts. Surveillance …